Stock Analysis
Avacta Group (LON:AVCT) Full Year 2023 Results
Key Financial Results
- Revenue: UK£23.2m (up 141% from FY 2022).
- Net loss: UK£24.9m (loss narrowed by 37% from FY 2022).
- UK£0.091 loss per share (improved from UK£0.15 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Avacta Group EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 10%.
Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the United Kingdom.
Performance of the British Biotechs industry.
The company's shares are up 2.8% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 4 warning signs for Avacta Group (of which 1 is potentially serious!) you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Avacta Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:AVCT
Avacta Group
Develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe.
Mediocre balance sheet and slightly overvalued.